ASTERASYS
Financials
Valuation Metrics
ASTERASYS's Market Cap is ₩2194B. At end of 2025 it was ₩4655B. Ranked #765 of 2,436 in KR market (top 31%), #338 of 1,649 on KOSDAQ (top 20%), #27 of 96 in Health Care Equipment & Services (top 28%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 219.37B KRW | KR#765/2,436 Sec#27/96 |
| Revenue | 38.72B KRW | KR#1,918/2,436 Sec#56/96 |
| Net Income | 7.73B KRW | KR#984/2,436 Sec#28/96 |
| Total Assets | 52.21B KRW | KR#2,170/2,436 Sec#73/96 |
| Net Assets | 44.16B KRW | KR#1,962/2,436 Sec#66/96 |
| Employees | 77 | KR#1,807/2,436 Sec#70/96 |
| Value | ||
| P/E | 28.39x | KR#1,238/2,436 Sec#40/96 |
| P/B | 4.97x | KR#2,236/2,436 Sec#82/96 |
| P/S | 5.66x | KR#2,173/2,436 Sec#75/96 |
| EV/EBITDA | 27.10x | KR#1,152/2,436 Sec#38/96 |
| FCF Yield | 1.62% | KR#1,099/2,436 Sec#31/96 |
| Profitability | ||
| ROE | 17.50% | KR#174/2,436 Sec#9/96 |
| ROA | 14.80% | KR#79/2,436 Sec#8/96 |
| Op. Margin | 20.71% | KR#138/2,436 Sec#11/96 |
| Revenue Growth | 11.67% | KR#862/2,436 Sec#39/96 |
| Earnings Growth | -283.31% | KR#1,556/2,436 Sec#52/96 |
| Financial Health | ||
| Debt Ratio | 118.23% | KR#615/2,436 Sec#28/96 |
| Total Debt | 1.00B KRW | KR#1,959/2,436 Sec#74/96 |
| FCF | 3.54B KRW | KR#988/2,436 Sec#27/96 |
| Cash | 3.06B KRW | KR#2,147/2,436 Sec#84/96 |
| Current Ratio | 5.51x | KR#258/2,436 Sec#18/96 |
| Net Debt/EBITDA | -0.26x | KR#634/2,436 Sec#25/96 |
| Dividend | ||
| Div. Yield | 1.88% | KR#929/2,436 Sec#23/96 |
| Div. Growth | 228.13% | KR#39/2,436 Sec#3/96 |
| Performance | ||
| 1Y Return | -42.28% | KR#1,892/2,436 Sec#68/96 |
| 1M Return | -16.95% | KR#2,093/2,436 Sec#81/96 |
| From 52W High | -66.65% | KR#2,023/2,436 Sec#73/96 |
| 1Y MDD | -68.94% | KR#1,906/2,436 Sec#67/96 |
| Trading | ||
| Volume | 20,062 shares | KR#1,843/2,436 Sec#76/96 |
| Foreign Own. | 0.47% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 208 KRW | KR#1,187/2,436 Sec#39/96 |
| BPS | 1,174 KRW | KR#2,246/2,436 Sec#84/96 |
Company Info
The company, Asterasys, established in 2015 for medical device manufacturing, is a small and medium-sized venture listed on KOSDAQ in 2025. It manufactures and sells anti-aging skin beauty devices using high-intensity focused ultrasound and non-invasive high-frequency, with Liftera as its main product. By the end of 2023, three new products were developed through KOL collaboration, and Coolfase and Coolsoniq obtained MFDS product approval. The company targets the global market after securing US FDA certification in 2026. Asterasys was established in 2015 and is headquartered in Seongdong-gu, Seoul.